BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines profit margin
Profit margin (net margin) is net income as a percentage of revenue.
BeOne Medicines's profit margin for the twelve months ending Sep 30, 2026 was 13.9%. For fiscal 2025 it was 5.4%, against -16.9% the year before. The highest annual figure on record is 5.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.4% | +22.3 |
| FY2024 | Dec 31, 2024 | -16.9% | +18.9 |
| FY2023 | Dec 31, 2023 | -35.9% | +105.7 |
| FY2022 | Dec 31, 2022 | -141.5% | −17.6 |
| FY2021 | Dec 31, 2021 | -123.9% | +402.2 |
| FY2020 | Dec 31, 2020 | -526.1% | −304.6 |
| FY2019 | Dec 31, 2019 | -221.5% | +118.4 |
| FY2018 | Dec 31, 2018 | -339.9% | −300.9 |
| FY2017 | Dec 31, 2017 | -39.1% | +11102.7 |
| FY2016 | Dec 31, 2016 | -11141.8% | −10494.1 |
| FY2015 | Dec 31, 2015 | -647.7% | −507.5 |
| FY2014 | Dec 31, 2014 | -140.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 20.4% | +11.5 |
| Q2 FY2026 | Jun 30, 2026 | 13.9% | +6.7 |
| Q1 FY2026 | Mar 31, 2026 | 15.0% | +14.9 |
| Q4 FY2025 | Dec 31, 2025 | 4.4% | +17.9 |
| Q3 FY2025 | Sep 30, 2025 | 8.8% | +21.0 |
| Q2 FY2025 | Jun 30, 2025 | 7.2% | +20.1 |
| Q1 FY2025 | Mar 31, 2025 | 0.1% | +33.5 |
| Q4 FY2024 | Dec 31, 2024 | -13.5% | +44.5 |
| Q3 FY2024 | Sep 30, 2024 | -12.1% | −39.7 |
| Q2 FY2024 | Jun 30, 2024 | -13.0% | +51.1 |
| Q1 FY2024 | Mar 31, 2024 | -33.4% | +44.4 |
| Q4 FY2023 | Dec 31, 2023 | -57.9% | +59.2 |
| Q3 FY2023 | Sep 30, 2023 | 27.6% | +171.4 |
| Q2 FY2023 | Jun 30, 2023 | -64.0% | +101.6 |
| Q1 FY2023 | Mar 31, 2023 | -77.8% | +64.1 |
| Q4 FY2022 | Dec 31, 2022 | -117.2% | +158.9 |
| Q3 FY2022 | Sep 30, 2022 | -143.8% | +68.4 |
| Q2 FY2022 | Jun 30, 2022 | -165.6% | +154.6 |
| Q1 FY2022 | Mar 31, 2022 | -141.9% | −152.9 |
| Q4 FY2021 | Dec 31, 2021 | -276.0% | +196.2 |
| Q3 FY2021 | Sep 30, 2021 | -212.2% | +254.6 |
| Q2 FY2021 | Jun 30, 2021 | -320.2% | +190.5 |
| Q1 FY2021 | Mar 31, 2021 | 11.0% | +709.7 |
| Q4 FY2020 | Dec 31, 2020 | -472.3% | +209.8 |
| Q3 FY2020 | Sep 30, 2020 | -466.9% | +146.1 |
| Q2 FY2020 | Jun 30, 2020 | -510.7% | −475.5 |
| Q1 FY2020 | Mar 31, 2020 | -698.7% | −483.3 |
| Q4 FY2019 | Dec 31, 2019 | -682.1% | −224.9 |
| Q3 FY2019 | Sep 30, 2019 | -613.0% | −347.3 |
| Q2 FY2019 | Jun 30, 2019 | -35.2% | +261.9 |
| Q1 FY2019 | Mar 31, 2019 | -215.4% | +106.0 |
| Q4 FY2018 | Dec 31, 2018 | -457.2% | +89.3 |
| Q3 FY2018 | Sep 30, 2018 | -265.7% | −319.0 |
| Q2 FY2018 | Jun 30, 2018 | -297.1% | – |
| Q1 FY2018 | Mar 31, 2018 | -321.4% | – |
| Q4 FY2017 | Dec 31, 2017 | -546.5% | – |
| Q3 FY2017 | Sep 30, 2017 | 53.3% | – |
See a number that looks wrong?